While generative AI has dominated the spotlight in the past year, machine learning programs have already been significantly impacting patients and physicians for several years. The question now arises: how will the emergence of programs like ChatGPT, coupled with increasing calls to scrutinize their safety, influence the adoption of new AI programs and diagnostics in healthcare?

AstraZeneca has the data to mount an attack on Pfizer’s dominance of a heart disease market. Friday, the Anglo-Swedish drugmaker reported positive top-line results from a phase 3 trial of acoramidis in Japan, teeing it up to file for regulatory approval in the country.

As clinical trials of its brain-computer interface progress, Synchron is laying the groundwork for the technology’s eventual commercial rollout.

Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday when the drugmaker axed (PDF) a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from its R&D pipeline.